Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$3.22 USD
+0.02 (0.63%)
Updated May 15, 2024 04:00 PM ET
After-Market: $3.24 +0.02 (0.62%) 7:30 PM ET
2-Buy of 5 2
D Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AQST 3.22 +0.02(0.63%)
Will AQST be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for AQST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AQST
Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics
Aquestive Therapeutics (AQST) Reports Q1 Loss, Misses Revenue Estimates
AQST: What are Zacks experts saying now?
Zacks Private Portfolio Services
Verrica Pharmaceuticals (VRCA) Moves 7.4% Higher: Will This Strength Last?
Carisma Therapeutics Inc. (CARM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Analysts Estimate Aquestive Therapeutics (AQST) to Report a Decline in Earnings: What to Look Out for
Other News for AQST
Oppenheimer Sticks to Its Buy Rating for Aquestive Therapeutics (AQST)
Buy Rating Justified for Aquestive Therapeutics Amidst Innovative Allergy Treatment and Strong Financial Prospects
Aquestive Therapeutics initiated with bullish view at Leerink, here's why
Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference
Oppenheimer Remains a Buy on Aquestive Therapeutics (AQST)